FDA
-
-
-
-
-
-
-
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
-
-
-
-
-
-
-
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
-
-
-
-
-
-
-
Edgewise Therapeutics names Michael Nofi as CFO
-
-
-
-
-
-
-
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Piper Sandler Sees 'Meaningful Upside Opportunities' for Edgewise Therapeutics (EWTX)
-
-
-
-
-
-
-
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
-
-
-
-
-
-
-
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
-
330,683 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

